These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32430255)

  • 1. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.
    Matulay JT; Tabayoyong W; Duplisea JJ; Chang C; Daneshmand S; Gore JL; Holzbeierlein JM; Karsh LI; Kim SP; Konety BR; Li R; McKiernan JM; Messing EM; Steinberg GD; Williams SB; Kamat AM
    Urol Oncol; 2020 Oct; 38(10):796.e1-796.e6. PubMed ID: 32430255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review.
    Mori K; Miura N; Babjuk M; Karakiewicz PI; Mostafaei H; Laukhtina E; Quhal F; Motlagh RS; Pradere B; Kimura S; Egawa S; Shariat SF
    Urol Oncol; 2020 Oct; 38(10):774-782. PubMed ID: 32654948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
    Choo SH; Nishiyama H; Kitamura H; Chen CH; Pu YS; Lee HL; Jeong BC; Kim SI
    Int J Urol; 2019 Dec; 26(12):1121-1127. PubMed ID: 31512280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranking Important Factors for Using Postoperative Chemotherapy in Nonmuscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    Cary C; Tong Y; Linsell S; Ghani K; Miller DC; Weiner M; Koch MO; Perkins SM; Zimet G
    J Urol; 2022 Feb; 207(2):293-301. PubMed ID: 34551594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Urological Association Nonmuscle Invasive Bladder Cancer Risk Model Validation-Should Patient Age be Added to the Risk Model?
    Ravvaz K; Weissert JA; Downs TM
    J Urol; 2019 Oct; 202(4):682-688. PubMed ID: 31188732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort.
    Ritch CR; Velasquez MC; Kwon D; Becerra MF; Soodana-Prakash N; Atluri VS; Almengo K; Alameddine M; Kineish O; Kava BR; Punnen S; Parekh DJ; Gonzalgo ML
    J Urol; 2020 Mar; 203(3):505-511. PubMed ID: 31609178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium.
    Fonteyne V; Rammant E; Ost P; Lievens Y; De Troyer B; Rottey S; De Meerleer G; De Maeseneer D; De Ridder D; Decaestecker K
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1159-e1169. PubMed ID: 30190222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors.
    Klaassen Z; Soloway MS
    Urology; 2017 Jul; 105():14-17. PubMed ID: 28366700
    [No Abstract]   [Full Text] [Related]  

  • 12. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
    Hendricksen K; Aziz A; Bes P; Chun FK; Dobruch J; Kluth LA; Gontero P; Necchi A; Noon AP; van Rhijn BWG; Rink M; Roghmann F; Rouprêt M; Seiler R; Shariat SF; Qvick B; Babjuk M; Xylinas E;
    Eur Urol Focus; 2019 Jul; 5(4):681-688. PubMed ID: 29074050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline of guidelines: non-muscle-invasive bladder cancer.
    Woldu SL; Bagrodia A; Lotan Y
    BJU Int; 2017 Mar; 119(3):371-380. PubMed ID: 28058776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familiarity and self-reported compliance with American Urological Association best practice recommendations for use of thromboembolic prophylaxis among American Urological Association members.
    Sterious S; Simhan J; Uzzo RG; Gershman B; Li T; Devarajan K; Canter D; Walton J; Fogg R; Ginzburg S; Corcoran A; Smaldone MC; Kutikov A
    J Urol; 2013 Sep; 190(3):992-8. PubMed ID: 23538239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of a Questionnaire-Based Study on Guideline Adherence Regarding Adjuvant Treatment Recommendations for Patients with Non-Muscle-Invasive Bladder Cancer: Just a Disturbing Sidelight?].
    Lebentrau S; Lebentrau J; May M; Wick AK; Mathew M; Schostak M
    Aktuelle Urol; 2016 Sep; 47(5):408-13. PubMed ID: 27299426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Implementation of the S3 prostate cancer guideline in daily clinical practice: results of a survey among urologists].
    Fröhner M; Khan C; Koch R; Schorr SG; Wirth M
    Urologe A; 2014 Oct; 53(10):1500-3. PubMed ID: 24984950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we following the guidelines on non-muscle invasive bladder cancer?
    Reis LO; Moro JC; Ribeiro LF; Voris BR; Sadi MV
    Int Braz J Urol; 2016; 42(1):22-8. PubMed ID: 27136464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Surveillance or Office Fulguration for Low Grade Ta Bladder Tumors: A Win-Win for Patients and Urologists.
    Soloway MS
    J Urol; 2018 May; 199(5):1120-1122. PubMed ID: 28987859
    [No Abstract]   [Full Text] [Related]  

  • 19. Micropapillary bladder cancer: current treatment patterns and review of the literature.
    Willis DL; Flaig TW; Hansel DE; Milowsky MI; Grubb RL; Al-Ahmadie HA; Plimack ER; Koppie TM; McConkey DJ; Dinney CP; Hoffman VA; Droller MJ; Messing E; Kamat AM
    Urol Oncol; 2014 Aug; 32(6):826-32. PubMed ID: 24931270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
    PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.